Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Voyageur Pharmaceuticals ( (TSE:VM) ) is now available.
Voyageur Pharmaceuticals has appointed Ethan Mohan as Executive Vice President, marking a strategic advancement in its leadership team. Mr. Mohan, previously the Sales Manager, will oversee corporate strategy, business development, and international market expansion. His promotion comes as Voyageur aims to capitalize on global opportunities in the radiographic contrast agent market, with a focus on sustainable and cost-efficient barium and iodine-based products. This move is expected to enhance Voyageur’s market presence and operational capabilities, positioning it as a leader in addressing the global demand for contrast media.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian public company focused on the development of barium and iodine Active Pharmaceutical Ingredients (API) for high-performance and cost-effective imaging contrast agents. The company aims to vertically integrate the barium and iodine contrast markets and is also pursuing the development of new endo fullerene drugs. Voyageur plans to generate cash flow by partnering with third-party GMP pharmaceutical manufacturers in Canada and aims to transition into a high-margin domestic manufacturer of radiology drugs.
YTD Price Performance: 111.11%
Average Trading Volume: 108,700
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$30.66M
Learn more about VM stock on TipRanks’ Stock Analysis page.